Sanofi (NASDAQ:SNY) has received FDA approval for Merilog, a biosimilar of Novo Nordisk's (NVO) rapid-acting insulin product NovoLog ... and 10 mL multiple-dose vial versions of the drug.

FDA drug alerts in endocrinology, including drug approvals, drug warnings, FDA medical device recalls, and FDA drug label ...

Insulin-aspart-szjj is the first rapid-acting insulin biosimilar approved and the third insulin product approved by the FDA.

It is the first biosimilar of a rapid-acting insulin ... dose vial should be administered by subcutaneous injection within five to 10 minutes before the start of a meal. NovoLog is also available ...

The US Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with diabetes mellitus.

The biosimilars – which will be interchangeable with Sanofi's Lantus (insulin glargine), Novo Nordisk's Novolog (insulin aspart ... at no more than $30 per vial and no more than $55 for a ...

Merilog will be provided by prefilled pen in a 3 mL dose or in a multiple-dose 10 mL vial ... commercial insurance. NovoLog and Novo Nordisk’s other rapid-acting insulin follow-on Fiasp are ...

During a hearing, representatives for the Newsom administration said they could not provide a timeline for when ...

Feb. 14, 2025 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Merilog (insulin-aspart-szjj) as biosimilar to Novolog (insulin ... multiple-dose vial. Merilog is the third ...

The U.S. Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with diabetes mellitus. Merilog is a ...